PERRIGO Co plc PRGO

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

Perrigo is a leading pure-play self-care company with more than a century of providing high-quality health and wellness solutions to meet the evolving needs of consumers. As one of the originators of the over-the-counter ("OTC") self-care market, Perrigo is led by its vision "To Provide The Best Self-Care For Everyone" and its purpose to "Make Lives Better Through Trusted Health and Wellness Solutions, Accessible To All".

Last close 15.96 2026-10-23
Market cap $2.21B 2026-06-27 share count
52-week range 9.22 - 22.01

Valuation FY2025 figures against the last close

P/S0.5x
P/E—
P/FCF15.3x
EV/EBITDA—
Dividend yield7.2%
Diluted EPS-10.29

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • Europe
  • All Other Countries
  • Other
Revenue by geography, 4 categories over 3 years. The same figures are in the table below. FY2025 United States, FY2025: 2.5B (59.1%) 59% United States Europe, FY2025: 1.6B (37.6%) 38% Europe All Other Countries, FY2025: 96.7M (2.3%) Other, FY2025: 42.1M (1.0%) FY2024 United States, FY2024: 2.6B (60.0%) 60% Europe, FY2024: 1.6B (36.4%) 36% All Other Countries, FY2024: 119.5M (2.7%) Other, FY2024: 39.6M (0.9%) FY2023 United States, FY2023: 2.9B (62.1%) 62% Europe, FY2023: 1.6B (34.5%) 35% All Other Countries, FY2023: 116.3M (2.5%) Other, FY2023: 40.8M (0.9%)
Region FY2025FY2024FY2023
United States $2.54B $2.65B $2.92B
Europe $1.62B $1.60B $1.62B
All Other Countries $96.7M $119.5M $116.3M
Other $42.1M $39.6M $40.8M

As the company reported it, from the “REVENUE RECOGNITION - Schedule of Net Sales by Geographic Locations (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $4.25B$4.37B$4.66B$4.45B$4.14B$4.09B$3.87B$4.73B$4.95B$5.28B
Cost of revenue $2.76B$2.83B$2.98B$3.00B$2.72B$2.59B$2.44B$2.90B$2.97B$3.23B
Gross profit $1.49B$1.54B$1.68B$1.46B$1.42B$1.49B$1.43B$1.83B$1.98B$2.05B
R&D $95.4M$112.2M$122.5M$123.1M$122.0M$121.7M$119.2M$218.6M$167.7M$184.0M
SG&A $435.9M$468.0M$522.3M$512.3M$482.0M$478.5M$476.5M$435.9M$461.1M$452.2M
Total operating expenses $2.62B$1.43B$1.53B$1.38B$1.01B$1.23B$1.26B$1.59B$1.38B$4.05B
Operating income -$1.12B$112.9M$151.9M$78.9M$410.4M$265.2M$174.7M$236.5M$598.2M-$2.00B
Interest expense ——$173.8M$156.0M$125.0M$127.7M$117.5M$128.0M$168.1M$216.6M
Pre-tax income -$1.30B-$80.7M-$8.3M-$139.1M$258.7M-$124.3M$156.8M$290.6M$280.1M-$4.85B
Income tax $104.4M$80.0M$3.9M$8.2M$389.6M$38.3M$10.7M$159.6M$160.5M$835.5M
Net income -$1.43B-$171.8M-$12.7M-$140.6M-$68.9M-$162.6M$146.1M$131.0M$119.6M-$4.01B
EPS, basic -10.29-1.25-0.09-1.04-0.52-1.201.070.950.84-28.01
EPS, diluted -10.29-1.25-0.09-1.04-0.52-1.191.070.950.84-28.01
Shares, diluted (wtd. avg.) 138.5M137.4M135.3M134.5M133.6M137.2M136.5M138.3M142.6M143.3M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $531.6M$558.8M$751.3M$600.7M$1.86B$631.5M$344.5M$541.9M$678.7M$622.3M
Receivables $612.8M$642.3M$739.6M$697.1M$652.9M$593.5M$1.24B$1.07B$1.13B$1.18B
Inventory $1.15B$1.08B$1.14B$1.15B$1.02B$1.06B$967.3M$878.0M$806.9M$795.0M
Total current assets $2.80B$2.48B$2.83B$2.72B$3.86B$3.13B$2.73B$2.90B$2.82B$2.81B
Property, plant and equipment $898.7M$917.8M$916.4M$926.3M$864.1M$864.6M$774.2M$829.1M$833.1M$870.1M
Goodwill $2.05B$3.32B$3.53B$3.49B$3.00B$3.10B$3.10B$3.98B$4.18B$4.05B
Other intangibles $4.76B$4.50B$5.00B$5.01B$3.68B$3.89B$4.75B$4.43B$4.75B$4.53B
Total assets $8.54B$9.65B$10.81B$11.02B$10.43B$11.49B$11.30B$10.98B$11.63B$13.87B
Accounts payable $474.5M$495.2M$477.7M$537.3M$411.2M$451.6M$520.2M$474.9M$450.2M$471.7M
Short-term debt $36.6M$36.4M$440.6M$36.2M$603.8M$37.3M$3.4M$190.2M$70.4M$572.8M
Total current liabilities $1.01B$1.04B$1.59B$1.11B$1.59B$1.38B$1.34B$1.54B$1.44B$1.84B
Long-term debt $3.60B$3.58B$3.63B$4.07B$2.92B$3.53B$3.37B$3.05B$3.27B$5.22B
Total liabilities $5.60B$5.33B$6.04B$6.18B$5.27B$5.83B$5.50B$5.32B$5.46B$7.91B
Retained earnings -$3.68B-$2.25B-$2.08B-$2.07B-$1.93B-$1.86B-$1.70B-$1.84B-$1.98B-$2.10B
Total equity $2.94B$4.32B$4.77B$4.84B$5.15B$5.66B$5.80B$5.67B$6.17B$5.96B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $238.5M$362.9M$405.5M$307.3M$156.3M$636.2M$387.8M$593.0M$698.9M$654.9M
Depreciation and amortisation $337.5M$325.9M$359.5M$338.6M$312.2M$384.8M$396.5M$423.6M$444.8M$457.0M
Stock-based compensation $54.6M$64.4M$68.8M$54.9M$60.1M$58.5M$52.2M$37.7M$43.8M$23.0M
Capital expenditure $93.4M$118.3M$101.7M$96.4M$152.1M$170.4M$137.7M$102.6M$88.6M$106.2M
Investing cash flow -$75.4M$78.8M-$77.5M-$1.96B$1.28B-$187.8M-$596.1M-$126.8M$2.34B-$175.0M
Financing cash flow -$220.5M-$611.0M-$187.2M$421.6M-$178.7M-$181.1M$1.8M-$571.9M-$3.00B-$268.7M
Dividends paid $159.3M$152.5M$149.7M$142.4M$129.6M$123.9M$112.4M$104.9M$91.1M$83.2M
Buybacks ———$0$0$164.2M$0$400.0M$191.5M$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001585364-26-000009.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -5B -2.5B 0 2.5B 5B 7.5B Revenue, FY2016: 5.3B Gross profit, FY2016: 2.1B Net income, FY2016: -4B Revenue, FY2017: 4.9B Gross profit, FY2017: 2B Net income, FY2017: 119.6M Revenue, FY2018: 4.7B Gross profit, FY2018: 1.8B Net income, FY2018: 131M Revenue, FY2019: 3.9B Gross profit, FY2019: 1.4B Net income, FY2019: 146.1M Revenue, FY2020: 4.1B Gross profit, FY2020: 1.5B Net income, FY2020: -162.6M Revenue, FY2021: 4.1B Gross profit, FY2021: 1.4B Net income, FY2021: -68.9M Revenue, FY2022: 4.5B Gross profit, FY2022: 1.5B Net income, FY2022: -140.6M Revenue, FY2023: 4.7B Gross profit, FY2023: 1.7B Net income, FY2023: -12.7M Revenue, FY2024: 4.4B Gross profit, FY2024: 1.5B Net income, FY2024: -171.8M Revenue, FY2025: 4.3B Gross profit, FY2025: 1.5B Net income, FY2025: -1.4B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $5.28B $4.95B $4.73B $3.87B $4.09B $4.14B $4.45B $4.66B $4.37B $4.25B
Gross profit $2.05B $1.98B $1.83B $1.43B $1.49B $1.42B $1.46B $1.68B $1.54B $1.49B
Net income -$4.01B $119.6M $131.0M $146.1M -$162.6M -$68.9M -$140.6M -$12.7M -$171.8M -$1.43B

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Officer or director change Item 5.02
  • Officer or director change Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
  • Regulation FD disclosure Item 7.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%